Article Information
History
- February 14, 2021.
Article Versions
- Version 1 (October 27, 2020 - 08:54).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Matthew J. Carr*,†,1,2,3,
- Alison K. Wright†,1,2,4,
- Lalantha Leelarathna2,4,5,
- Hood Thabit2,4,5,
- Nicola Milne2,5,
- Naresh Kanumilli2,5,
- Darren M. Ashcroft†,1,2,3 and
- Martin K. Rutter†,2,4,5
- 1Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK
- 2Manchester Academic Health Science Centre
- 3NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, UK
- 4Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
- 5Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, Manchester, UK
- ↵*Corresponding Author: Matthew J. Carr, PhD Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, The University of Manchester, 1st Floor, Stopford Building, Oxford Road, Manchester, M13 9PT. Tel: +44 161 287 6880. matthew.carr{at}manchester.ac.uk
↵† Equal contribution
Posted February 14, 2021.
Impact of COVID-19 on diagnoses, monitoring and mortality in people with type 2 diabetes: a UK-wide cohort study involving 14 million people in primary care
